Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KF; Steering Committee. Lip GY, et al. Among authors: olsson sb. Eur Heart J. 2009 Dec;30(23):2897-907. doi: 10.1093/eurheartj/ehp318. Epub 2009 Aug 18. Eur Heart J. 2009. PMID: 19690349 Free PMC article. Clinical Trial.
Diurnal variations of the dominant cycle length of chronic atrial fibrillation.
Meurling CJ, Waktare JE, Holmqvist F, Hedman A, Camm AJ, Olsson SB, Malik M. Meurling CJ, et al. Among authors: olsson sb. Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H401-6. doi: 10.1152/ajpheart.2001.280.1.H401. Am J Physiol Heart Circ Physiol. 2001. PMID: 11123257 Free article.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Lip GY, Rasmussen LH, Olsson SB, Zetterstrand S, Stahre C, Bylock A, Aunes-Jansson M, Eriksson U, Wåhlander K; Steering Committee. Lip GY, et al. Among authors: olsson sb. Thromb Res. 2011 Feb;127(2):91-9. doi: 10.1016/j.thromres.2010.11.012. Epub 2010 Dec 18. Thromb Res. 2011. PMID: 21172721 Clinical Trial.
[ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary].
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association; European Society of Cardiology. Fuster V, et al. Among authors: olsson sb. Rev Port Cardiol. 2007 Apr;26(4):383-446. Rev Port Cardiol. 2007. PMID: 17695733 Portuguese. No abstract available.
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Heuzey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Yancy CW. Wann LS, et al. Among authors: olsson sb. Heart Rhythm. 2011 Mar;8(3):e1-8. doi: 10.1016/j.hrthm.2011.01.032. Epub 2011 Feb 13. Heart Rhythm. 2011. PMID: 21324421 No abstract available.
273 results